Abstract
Summary
The concept of inadequate response to osteoporosis treatment is not clear. In the literature several criteria have been used. We propose an operational definition of an inadequate responder based on the changes observed in bone mineral density and incident fractures while on therapy.
Introduction
Fractures may occur in compliant patients even while on active treatment. These cases have been defined as inadequate responders (IR).
Methods
We reviewed the basis for this concept and propose an operational definition for IR.
Results
Good compliance and adequate calcium and vitamin D supplementation are the first requirement. The second requirement is a treatment period of at least 1 year, since before that time treatment may not have been fully effective. Fractures are the gold standard for measuring efficacy and changes in bone density and turnover markers may be surrogates. We propose classifying patient response as: Inadequate—incident fracture and a decrease in BMD greater than a significant change (Trend Assessment Margin or TAM); Possibly inadequate—incident fracture or a decrease in BMD greater than a significant change (TAM); and Appropriate—no fracture and no decrease in BMD greater than a significant change (TAM). Additional criteria (biochemical markers, bone quality parameters) may be taken into account.
Conclusion
A wide consensus on the IR concept is required given its clinical, regulatory, and reimbursement implications.
Similar content being viewed by others
References
Cramer JA, Gold DT, Silverman SL et al (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031
Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008
Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352
Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645
Chesnut CH III, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 109:267–276
Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Adami S, Isaia G, Luisetto G et al (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565–1570
Hugen PW, Langebeek N, Burger DM et al (2002) Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 30:324–334
Nieuwkerk PT, Oort FJ (2005) Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr 38:445–448
Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16:269–277
Arnsten JH, Demas PA, Farzadegan H et al (2001) Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 33:1417–1423
Fletcher CV, Testa MA, Brundage RC et al (2005) Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr 40:301–306
Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135
Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468
Seeman E (2007) Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy. Bone 41:308–317
Dempster DW (2002) Bone remodeling. In: Coe FL, Favus MJ (eds) (2002) Disorders of bone and mineral metabolism, 2nd edn. Lippincott Williams and Wilkins, Baltimore, pp 315–343
Diez-Perez A, Gonzalez-Macias J, Marin F et al (2007) Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound. Osteoporos Int 18:629–639
Baim S, Wilson CR, Lewiecki EM et al (2005) Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 8:371–378
Gluer CC (1999) Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14:1952–1962
Lodder MC, Lems WF, Ader HJ et al (2004) Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis 63:285–289
Sarkar S, Reginster JY, Crans GG et al (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Min Res 19:394–401
Chapurlat RD, Palermo L, Ramsay P, Cummings SR (2005) Risk of fracture among women who lose bone density during treatment with alendronate: the Fracture Intervention Trial. Osteoporos Int 16:842–848
Lenchik L, Kiebzak GM, Blunt BA (2002) International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. What is the role of serial bone mineral density measurements in patient management. J Clin Densitom 5 [Suppl]:S29–S38
Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 19:1250–1258
Barrett-Connor E (1991) Nutrition epidemiology: how do we know what they ate. Am J Clin Nutr 54 [Suppl 1]:182S–187S
Gaugris S, Heaney RP, Boonen S et al (2005) Vitamin D inadequacy among post-menopausal women: a systematic review. QJM 98:667–676
Dixon T, Mitchell P, Beringer T et al (2006) An overview of the prevalence of 25-hydroxy-vitamin D inadequacy amongst elderly patients with or without fragility fracture in the United Kingdom. Curr Med Res Opin 22:405–415
Wilkins CH, Birge SJ (2005) Prevention of osteoporotic fractures in the elderly. Am J Med 118:1190–1195
Jackson C, Gaugris S, Sen SS et al (2007) The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM 100:185–192
Del Puente A, Scognamiglio A, Itto E et al (2000) Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol 27:1980–1983
Heckman GA, Papaioannou A, Sebaldt RJ et al (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6
Sawka AM, Adachi JD, Ioannidis G et al (2003) What predicts early fracture or bone loss on bisphosphonate therapy. J Clin Densitom 6:315–322
Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6:307–314
National Institute for Clinical Excellence (2004) Final appraisal determination—secondary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/page.aspx?o=115560
Jakob F, Marin F, Martin-Mola E et al (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 99:531–543
Obermayer-Pietsch BM, Nickelsen T, Marin F et al (2006) Response of BMD to 24 months of teriparatide (rhPTH 1–34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS Study. J Bone Miner Res 21 [Suppl 1]:S43
Sarkar S, Mitlak BH, Wong M et al (2002) Relationship between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Min Res 17:1–10
Khosla S (2003) Surrogates for fracture endpoints in clinical trials. J Bone Min Res 18:1146–1149
Sebba AI, Bonnick SL, Kagan R et al (2004) Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20:2031–2041
Ferrar L, Jiang G, Armbrecht G et al (2007) Is short vertebral height always an osteoporotic fracture? The Osteoporosis and Ultrasound Study (OPUS). Bone 41:5–12
Ohlendorff SD, Tofteng CL, Jensen JE et al (2007) Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics 17:555–567
Rapuri PB, Gallagher JC, Knezetic JA et al (2006) Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas 53:371–379
Yahata T, Quan J, Tamura N et al (2005) Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women. Hum Reprod 20:1860–1866
Tofteng CL, Abrahamsen B, Jensen JE et al (2004) Two single nucleotide polymorphisms in the CYP17 and COMT Genes—relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study. Calcif Tissue Int 75:123–132
Morrison NA, George PM, Vaughan T et al (2005) Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet Genomics 15:127–135
Steines D, Arnaud C, Liew S et al (2005) Predicting hip fracture in a sub-group of subjects from the study of osteoporotic fractures using automated structural measurements of proximal femur in pelvic radiographs. J Bone Miner Res 20 [Suppl 1]:F090
Rivadeneira F, Zillikens MC, De Laet CE et al (2007) Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. J Bone Miner Res 22:1781–1790
Hernandez CJ, Gupta A, Keaveny TM (2006) A biomechanical analysis of the effects of resorption cavities on cancellous bone strength. J Bone Miner Res 21:1248–1255
Ladinsky GA, Vasilic B, Popescu AM et al (2008) Trabecular structure quantified with the MRI-based virtual bone biopsy in postmenopausal women contributes to vertebral deformity burden independent of areal vertebral BMD. J Bone Miner Res 23:64–74
Acknowledgements
The authors wish to thank Fernando Marin, M.D. for useful comments and Christine O’Hara for invaluable help with the English version of the manuscript. The study was supported in part by an official grant from the Spanish Ministry of Health (Fondo de Investigaciones Sanitarias [FIS] number PI052233).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Díez-Pérez, A., González-Macías, J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 19, 1511–1516 (2008). https://doi.org/10.1007/s00198-008-0659-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-008-0659-2